Fulcrum Therapeutics will present at two upcoming investor conferences, discussing small molecules for rare genetic diseases, particularly sickle cell disease.
Quiver AI Summary
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for genetically defined rare diseases, announced that its management team will present at two upcoming investor conferences in New York City: the Cantor Fitzgerald Annual Global Healthcare Conference on September 4, and the H.C. Wainwright Annual Global Investment Conference on September 9. Fulcrum's key program is pociredir, an investigational small molecule aimed at increasing fetal hemoglobin levels to treat sickle cell disease (SCD). After a clinical hold was lifted by the FDA, pociredir has demonstrated safety and proof-of-concept in increasing hemoglobin levels in patients with SCD and has received FDA Fast Track and Orphan Drug designations. Investors interested in one-on-one meetings can reach out to conference representatives, and recordings of the presentations will be available on the company's website post-events.
Potential Positives
- Fulcrum Therapeutics announced participation in two significant investor conferences, enhancing visibility and engagement with potential investors.
- The company’s lead program, pociredir, has received FDA Fast Track and Orphan Drug Designations, highlighting its potential to address urgent medical needs in treating sickle cell disease.
- Pociredir demonstrated proof-of-concept in initial clinical trials, indicating substantial benefits for patients suffering from sickle cell disease, which strengthens the company's clinical value proposition.
- The lifting of the FDA clinical hold in August 2023 allows Fulcrum to move forward with its clinical trials, potentially accelerating the development of pociredir.
Potential Negatives
- The press release does not provide any new data or updates on the development progress of pociredir, which could leave investors concerned about the status of the drug.
- The mention of a clinical hold prior to the lifting by the FDA may raise concerns regarding the reliability and safety of pociredir, potentially affecting investor confidence.
- There is no detailed information regarding the timelines for further clinical trials or potential market entry, leading to uncertainty about future growth and revenue projections.
FAQ
What conferences will Fulcrum Therapeutics attend in September 2025?
Fulcrum Therapeutics will attend the Cantor Fitzgerald Global Healthcare Conference and H.C. Wainwright Global Investment Conference.
Who will present at the investor conferences?
Presenters include Alex Sapir, Chief Executive Officer; Alan Musso, Chief Financial Officer; and Iain Fraser, Senior Vice President of Early Development.
What is Pociredir and what condition does it target?
Pociredir is an investigational oral small-molecule designed to increase fetal hemoglobin for the treatment of sickle cell disease.
How can investors request one-on-one meetings during the conferences?
Interested investors should contact their respective representative at the sponsoring institutions to request one-on-one meetings.
What designations has Pociredir received from the FDA?
Pociredir has been granted FDA Fast Track designation and Orphan Drug Designation for the treatment of sickle cell disease.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$FULC Insider Trading Activity
$FULC insiders have traded $FULC stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $FULC stock by insiders over the last 6 months:
- GREG TOURANGEAU (Principal Accounting Officer) sold 498 shares for an estimated $2,519
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$FULC Hedge Fund Activity
We have seen 58 institutional investors add shares of $FULC stock to their portfolio, and 79 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ADAGE CAPITAL PARTNERS GP, L.L.C. added 1,589,000 shares (+53.0%) to their portfolio in Q2 2025, for an estimated $10,932,320
- BALYASNY ASSET MANAGEMENT L.P. added 1,338,214 shares (+inf%) to their portfolio in Q2 2025, for an estimated $9,206,912
- GOLDMAN SACHS GROUP INC added 740,936 shares (+184.0%) to their portfolio in Q2 2025, for an estimated $5,097,639
- D. E. SHAW & CO., INC. added 596,050 shares (+102.7%) to their portfolio in Q2 2025, for an estimated $4,100,824
- NANTAHALA CAPITAL MANAGEMENT, LLC removed 534,394 shares (-11.1%) from their portfolio in Q2 2025, for an estimated $3,676,630
- POINT72 ASSET MANAGEMENT, L.P. added 498,219 shares (+inf%) to their portfolio in Q2 2025, for an estimated $3,427,746
- ADAR1 CAPITAL MANAGEMENT, LLC removed 437,183 shares (-89.1%) from their portfolio in Q2 2025, for an estimated $3,007,819
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$FULC Analyst Ratings
Wall Street analysts have issued reports on $FULC in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 07/29/2025
- Piper Sandler issued a "Overweight" rating on 05/29/2025
- Leerink Partners issued a "Outperform" rating on 05/23/2025
- Cantor Fitzgerald issued a "Overweight" rating on 05/15/2025
To track analyst ratings and price targets for $FULC, check out Quiver Quantitative's $FULC forecast page.
$FULC Price Targets
Multiple analysts have issued price targets for $FULC recently. We have seen 5 analysts offer price targets for $FULC in the last 6 months, with a median target of $10.0.
Here are some recent targets:
- Luca Issi from RBC Capital set a target price of $5.0 on 07/30/2025
- Andrew Fein from HC Wainwright & Co. set a target price of $12.0 on 07/29/2025
- Edward Tenthoff from Piper Sandler set a target price of $9.0 on 05/29/2025
- Joseph Schwartz from Leerink Partners set a target price of $12.0 on 05/23/2025
- Kristen Kluska from Cantor Fitzgerald set a target price of $10.0 on 05/15/2025
Full Release
CAMBRIDGE, Mass., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that company management will attend and present at the following investor conferences:
Cantor Fitzgerald 2025 Annual Global Healthcare Conference
- Location: New York, NY, U.S.
- Date: September 4, 2025
- Time: 1:35-2:05 PM ET
- Type: Fireside chat
- Presenters: Alex Sapir, Chief Executive Officer; Alan Musso, Chief Financial Officer; Iain Fraser, Senior Vice President of Early Development
- Webcast: Link
H.C. Wainwright 27th Annual Global Investment Conference
- Location: New York, NY, U.S.
- Date: September 9, 2025
- Time: 2:00-2:30 PM ET
- Type: Company presentation
- Presenters: Alex Sapir, Chief Executive Officer; Alan Musso, Chief Financial Officer; Iain Fraser, Senior Vice President of Early Development
- Webcast: Link
Fulcrum management will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
Following the events, webcast replay links will be posted to Fulcrum Therapeutics Investor Relations’ Events and Presentations page.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s lead clinical program is pociredir, a small molecule designed to increase expression of fetal hemoglobin (HbF) for the treatment of sickle cell disease (SCD). Fulcrum uses proprietary technology to identify drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, visit
www.fulcrumtx.com
and follow us on Twitter/X (@FulcrumTx) and LinkedIn.
About Pociredir
Pociredir is an investigational oral small-molecule inhibitor of Embryonic Ectoderm Development (EED) that was discovered using Fulcrum’s proprietary discovery technology. Inhibition of EED leads to potent downregulation of key fetal globin repressors, including BCL11A, thereby causing an increase in fetal hemoglobin (HbF). Pociredir is being developed for the treatment of SCD. Initial data in SCD demonstrated proof-of-concept and achieved absolute levels of HbF increases associated with potential overall patient benefit. In clinical trials conducted prior to the clinical hold, which was lifted by the FDA in August 2023, pociredir was generally well-tolerated in people with SCD with up to three months of exposure, with no serious treatment-related adverse events reported. Pociredir has been granted FDA Fast Track designation and Orphan Drug Designation for the treatment of SCD. To learn more about these trials please visit
ClinicalTrials.gov
.
About Sickle Cell Disease
Sickle cell disease (SCD) is a genetic disorder of the red blood cells caused by a mutation in the HBB gene. This gene encodes a protein that is a key component of hemoglobin, a protein complex whose function is to transport oxygen in the body. The result of the mutation is less efficient oxygen transport and the formation of red blood cells that have a sickle shape. These sickle shaped cells are much less flexible than healthy cells and can block blood vessels or rupture cells. People with SCD typically suffer from serious clinical consequences, which may include anemia, pain, infections, stroke, heart disease, pulmonary hypertension, kidney failure, liver disease, and reduced life expectancy.
Contact:
Kevin Gardner
LifeSci Advisors, LLC
[email protected]
617-283-2856
